Linked Life Data

11781624

Source:http://linkedlifedata.com/resource/pubmed/id/11781624

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2002-1-8
pubmed:abstractText
The efficacy of allogeneic, haemopoietic stem cell transplantation (HSCT) is limited by concomitant toxicity. This has led to the development of less toxic, reduced intensity conditioning (RIC) protocols, whose therapeutic benefit is largely related to an associated, immunity-mediated graft-versus-malignancy effect rather than by the cytotoxic treatment itself. Murine HSCT models suggests that acute graft-versus-host disease (GVHD) increases with the intensification of the conditioning regimen mediated by loss of integrity of the gut mucosa barrier. The present study was undertaken to investigate gastro-intestinal (GI) permeability during allogeneic HSCT with RIC. In 17 patients (myeloablative conditioning in nine, RIC in eight), intestinal permeability was assessed by a (51)Cr-EDTA absorption test before the start of cytotoxic treatment the day before stem cell infusion (day -1) and 4, 7 and 14 days after stem cell infusion. Patients receiving RIC did not develop any significant increase in intestinal permeability during the transplantation course but in myeloablatively conditioned patients there was a significant increase in intestinal permeability the day before the stem cell infusion (P < 0.005), on day 4 (P < 0.005), on day 7 (P < 0.01) and on day 14 (P < 0.005) after stem cell infusion, compared with the baseline. Myeloablative conditioning also revealed increased intestinal permeability on day 7 compared with the RIC (P < 0.05). The finding of preserved intestinal-barrier function during allogeneic HSCT with RIC is discussed, with reference to the hypothesis that GI tract damage may be an important initiating event of GVHD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
737-42
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11781624-Adult, pubmed-meshheading:11781624-Antilymphocyte Serum, pubmed-meshheading:11781624-Antineoplastic Agents, pubmed-meshheading:11781624-Busulfan, pubmed-meshheading:11781624-Cyclophosphamide, pubmed-meshheading:11781624-Female, pubmed-meshheading:11781624-Gastric Mucosa, pubmed-meshheading:11781624-Graft Survival, pubmed-meshheading:11781624-Graft vs Host Disease, pubmed-meshheading:11781624-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11781624-Humans, pubmed-meshheading:11781624-Intestinal Absorption, pubmed-meshheading:11781624-Intestinal Mucosa, pubmed-meshheading:11781624-Male, pubmed-meshheading:11781624-Middle Aged, pubmed-meshheading:11781624-Permeability, pubmed-meshheading:11781624-Prospective Studies, pubmed-meshheading:11781624-T-Lymphocytes, pubmed-meshheading:11781624-Transplantation, Homologous, pubmed-meshheading:11781624-Transplantation Conditioning, pubmed-meshheading:11781624-Treatment Outcome, pubmed-meshheading:11781624-Vidarabine, pubmed-meshheading:11781624-Whole-Body Irradiation
pubmed:year
2001
pubmed:articleTitle
The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
pubmed:affiliation
Department of Haematology, Sahlgrenska University Hospital, Faculty of Medicine, University of Göteborg, Göteborg, Sweden.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't